Research programme: CD95 antibody therapeutics - Amorfix Life Sciences
Alternative Names: Anti-Fas antibodies - AmorfixLatest Information Update: 18 Dec 2014
At a glance
- Originator Amorfix Life Sciences
- Developer ProMIS Neurosciences
- Class Monoclonal antibodies
- Mechanism of Action CD95 antigen stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Suspended Cancer
Most Recent Events
- 08 Aug 2014 Suspended for Cancer in Canada (Parenteral)
- 18 Jul 2012 Research is ongoing in Canada
- 18 Jul 2012 Research programme is available for licensing as of 30 Apr 2012. http://www.amorfix.com